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Summary
Objective: Glucosamine (GLN) and chondroitin sulfate (CS) are widely used to alleviate symptoms of osteoarthritis (OA). However, the
mechanism(s) of action of these nutraceuticals remains unresolved. In the present study, we determined the effect of physiologically relevant
concentrations of GLN and CS on gene expression and synthesis of nitric oxide (NO) and prostaglandin E2 (PGE2) in cytokine-stimulated
articular cartilage explants.
Methods: Using bovine articular cartilage explants in culture stimulated with IL-1, the effects of physiologically relevant concentrations of GLN
and CS on gene expression of inducible nitric oxide synthase (iNOS), endothelial nitric oxide synthase (eNOS), cyclooxygenase-2 (COX-2)
and microsomal prostaglandin E synthase-1 (mPGEs1) were assessed with quantitative real-time polymerase chain reaction (Q-RT-PCR).
The production of NO and PGE2 was also quantiﬁed.
Results: CS and the GLN and CS combination at concentrations attainable in the blood down-regulated IL-1 induced mRNA expression of
iNOS at 24 and 48 h post-culture. Up-regulated iNOS expression at 24 h by IL-1 was also suppressed by GLN. GLN and CS transiently
repressed the cytokine-stimulated mPGEs1 transcript. Synthesis of NO was reduced with CS alone and the combination after 24 h of culture.
Repression of COX-2 transcripts by GLN and CS was accompanied by concomitant reduction in PGE2.
Conclusion: Our results indicate that physiologically relevant concentrations of GLN and CS can regulate gene expression and synthesis of
NO and PGE2, providing a plausible explanation for their purported anti-inﬂammatory properties.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is characterized by the degeneration of
matrix components of articular cartilage accompanied with
an excess production of proinﬂammatory cytokines1. In-
terleukin-1 (IL-1) beta is widely accepted as one of the
proinﬂammatory cytokines that plays a pivotal role in the
pathophysiology of OA2. It induces a cascade of catabolic
events in chondrocytes including the up-regulation in genes
of matrix metalloproteinases (MMPs), inducible nitric oxide
synthase (iNOS), cyclooxygenase-2 (COX-2) and micro-
somal prostaglandin E synthase-1 (mPGEs1) and the
release of nitric oxide (NO) and prostaglandin E2 (PGE2)
3e6.
IL-1 also retards anabolic activities of the chondrocytes
leading to declines in proteoglycan synthesis and collagen
synthesis7,8.
NO is produced from L-arginine catalyzed by a family of
NO synthases9e11. The constitutive isoforms are endothe-
lial nitric oxide synthase (eNOS) and neuronal nitric oxide
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Received 26 June 2004; revision accepted 4 January 2005.38synthase (nNOS). An elevated level of iNOS is responsible
for the secretion of NO, an inorganic free radical, in large
amount from OA cartilage. NO oxide promotes inﬂammation
and articular cartilage degeneration by increasing cytokine
production, suppressing matrix synthesis, elevating MMPs
and inactivating tissue inhibitors of metalloproteinases
(TIMPs)12e14.
PGE2 mediates inﬂammatory and pain responses, and is
the most abundant prostanoid found in the diseased joint15.
COX and PGE synthases are rate-limiting enzymes re-
sponsible for generating PGE2. The inducible form of this
enzyme is COX-2, which catalyzes the conversion of
arachidonic acid to prostaglandin H2 (PGH2) and mPGEs1,
which isomerizes PGH2 to PGE2. The synthesis of PGE2
correlates with up-regulation of COX-2 and mPGEs16,16.
PGE2 elicits its catabolic effect on articular cartilage by
enhancing MMP production and proteoglycan degradation
and by inhibiting synthesis of TIMPs17,18.
Various compounds have been used in palliative treat-
ment of OA. Two compounds that are increasing in favor as
a treatment option for joint diseases both in humans and
animals are glucosamine (GLN) and chondroitin sulfate
(CS). These compounds are termed nutraceuticals because
they have both nutrient and pharmaceutical properties.
They have been used over the past 30 years for the
treatment of OA and shown in several animal and human7
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degeneration, pain, and inﬂammation. In animals, the
combination reduces lameness in dogs and horses and is
effective in managing pain in cats19e21. GLN and CS used
alone or in combination can decrease joint space narrow-
ing, alleviate pain, and improve joint mobility in humans
affected with knee OA22e25.
Elucidating the mechanism(s) of action of GLN and CS in
vivo is an active area of research. Pain amelioration with
GLN and CS may be attributed to a reduction in in-
ﬂammatory mediators. In vitro, cytokine-stressed cartilage
explants treated with GLN demonstrated a decline in iNOS
transcript and NO release into the media26e30. Parallel with
the inhibition of COX-2, PGE2 production and release was
also inhibited with GLN26,28,31. CS possesses anti-inﬂam-
matory properties32.
To date, the majority of in vitro research has been per-
formedwith concentrations ofGLNandCS that exceed those
likely to be obtained by oral administration26e28,31,33e35. This
was one of the reasons given by rheumatologists in their
objection to recommending GLN to patients36. The concen-
trations of GLN in serum after oral and intravenous
administration range from 1 to 20 mg/ml while CS concen-
trations are in the 5e200 mg/ml range depending on the route
of administration, species and the molecular weight of
CS37e42. Thus, the aim of the present study was to determine
the effect of concentrations of GLN (5 mg/ml) and CS (20 mg/
ml) that have been attained in blood on mRNA expression of
iNOS, eNOS, COX-2 andmPGEs1 and the production of NO
and PGE2 in articular cartilage explants stimulated with IL-1,
a cytokine associated with cartilage catabolism.
Materials and methods
EXPLANT CULTURES
Articular cartilage was isolated from the carpal joints of
Holstein steers (18e24 months old) obtained from a local
abattoir within 3 h of slaughter. Cartilage discs (6 mm) were
biopsied from the articular surface and did not include
cartilage with gross characteristics of OA and calciﬁed
cartilage. Two explant discs (approximately 60 mg total wet
weight) were randomly picked and cultured in each well of
a 24-well Falcon culture plate (Fisher Scientiﬁc, Pittsburgh,
PA, USA) containing 1 ml of 1:1 modiﬁed version of
Dulbecco’s modiﬁed Eagle’s medium:nutrient mixture F-12
(Ham) (Gibco, Grand Island, NY, USA), as previously
described27. The media were supplemented with 20 amino
acids (Sigma, St. Louis, MO, USA), 50 mg/ml ascorbic acid,
and 100 units/ml penicillin/streptomycin (Gibco). The con-
centrations of amino acids added were 50% of those
previously reported43. Cartilage explants were housed in
a humidiﬁed incubator at 37(C with 7% CO2.
Explants were maintained in media without serum for 2
equilibration days prior to the addition of treatments. After
equilibration, all treatments received 10% fetal bovine serum
(FBS, Gibco) and 50 ng/ml of human recombinant IL-1 beta
(rhIL-1b, R & D Systems, Minneapolis, MN, USA) added to
induce cartilage catabolism. The concentrations of GLN HCl
(5 mg/ml; FCHG49,NutramaxLaboratories,Edgewood,MD,
USA) and low molecular weight (16.9 kDa) CS (20 mg/ml;
TRH122, Nutramax Laboratories) chosen were well within
the range of levels measured in the blood37,41. There were
ﬁve treatments per experiment (Table I), an FBS control
(Ctrl), 50 ng/ml rhIL-1b (IL-1), 50 ng/ml rhIL-1b with the
addition of 5 mg/ml GLN (IL-1CGLN), 50 ng/ml rhIL-1b with
the addition of 20 mg/ml CS (IL-1CCS) and 50 ng/ml rhIL-1bwith the addition of both GLN and CS (IL-1CGLNCCS).
Each treatment consisted of 24 discs (12 wells) collected
from a pool of three steers for an experiment. Cartilage discs
were collected 6, 24and48 hpost-stimulation, frozen in liquid
nitrogen and stored at 80(C until RNA isolation. Condi-
tionedmedia were collected at 24 and 48 h and stored at 4(C
for nitrite and PGE2 analysis. Experiment was repeated
a total of three times for each time point, each time using
tissue from a pool of three different animals.
NO ASSAY
Nitrite is a stable end product of NO metabolism and was
measured in conditioned media using the Griess reagent
and sodium nitrite as standard44. Brieﬂy, 150 ml medium
was incubated with 150 ml of 1.0% sulfanilamide, 0.1% N-1-
napthylethylenediamide hydrochloride and 25% phosphoric
acid at room temperature for 5 min. Due to some pre-
cipitation of reagents with CS, 96-well plates were spun at
3250 rpm for 3 min at 4(C. The remaining supernatant was
transferred to a new plate. Absorbance was measured at
540 nm using a Spectromax 300 plate reader (Molecular
Devices, Sunnyvale, CA, USA).
PGE2 ASSAY
PGE2 release into conditioned media was quantiﬁed
using a commercially available competitive enzyme linked
immunosorbent assay kit (R & D Systems). Indomethacin
(10 mg/ml) was added to conditioned media samples
collected at 24 and 48 h post-stimulation to inhibit any
prostaglandin synthase present, and stored at 20(C until
analysis. Samples were run according to the manufacturer’s
instructions. Absorbance was determined at 405 nm with
a wavelength correction set at 590 nm.
TOTAL RNA ISOLATION
The extraction of RNA from explants was performed
following amodiﬁed protocol45. Brieﬂy, cartilage was homog-
enized in TRIzol reagent (Invitrogen, Carlsbad, CA, USA),
chloroform was added to extract total RNA followed by
vigorous agitation and a 2 min incubation. The aqueous
phase containing RNA was collected after centrifugation
and the RNA was precipitated with ethanol. Total RNA was
then puriﬁed further with RNeasy mini columns (Qiagen,
Valencia, CA, USA) and quantiﬁed by UV spectrophotom-
etry (Beckman Coulter, Fullerton, CA, USA). Total chon-
drocyte RNA was resolved on 1.2% agarose gel to validate
spectrophotometric determinations and RNA integrity.
CDNA SYNTHESIS
For each sample, 2 mg of RNA was treated with DNase I
(Invitrogen) to degrade contaminating single and double
Table I
Description of components found in treatment media of explant
cultures
Treatment FBS
(%)
rhIL-1b (IL-1)
(ng/ml)
GLN
(mg/ml)
CS
(mg/ml)
Ctrl 10 e e e
IL-1 10 50 e e
IL-1CGLN 10 50 5 e
IL-1CCS 10 50 e 20
IL-1CGLNCCS 10 50 5 20
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Forward and reverse primers (5#/3#) used for Q-RT-PCR
Gene GenBank accession number Forward primer
(concentration in nM)
Reverse primer
(concentration in nM)
GAPDH AB098979 GCATCGTGGAGGGACTTATGA (50) GGGCCATCCACAGTCTTCTG (50)
iNOS AF333248 CCCGCATGCAACTCCAA (50) TCGTAAGTCATGAACTGCCACTTC (50)
eNOS NM_181037 CGCTGTCCTGTTGGCCTTTA (300) GACCTAGAGATGAGAGGATGAGATAGTACA (300)
COX-2 AF004944 GCACAAATCTGATGTTTGCATTC (300) GGTCCTCGTTCAAAATCTGTCTTG (300)
mPGEs1 NM_174443 GTACGTGGTGGCCGTCATC (300) GGGTTGGCAAAAGCCTTCTT (900)stranded DNA. Treated RNA was converted to single
stranded cDNA using Superscript II reverse transcriptase
(Invitrogen) as recommended by the manufacturer. Single
stranded cDNA was quantiﬁed with UV spectrophotometry
(Beckman Coulter) and diluted to 50 ng/ml.
QUANTITATIVE REAL-TIME POLYMERASE CHAIN
REACTION (Q-RT-PCR)
Primers for glyceraldehyde phosphate dehydrogenase
(GAPDH, usedas ahousekeeping gene) andmolecules from
Table II were designed using the Primer Express software
version 2.0 (Applied Biosystems, Foster City, CA, USA).
Optimal concentrations of each set of primers were deter-
minedwith a PrimerMatrix (lowest standard deviationwith no
change in cycle to threshold (Ct)). Q-RT-PCRwas performed
with 50 ng cDNA templates in 96-well plates using the ABI
PRISM 7000 sequence detection system (Applied Biosys-
tems). The analysis of each sample was performed in
duplicate. The cDNA templates were combined with optimal
concentrations of primers and SYBR Green PCR dye mix
(Applied Biosystems) in a total volume of 50 ml and the
ampliﬁcation conducted as recommended by manufacturer.
The PCR conditions were 2 min at 50(C and 10 min at
95(C followed by 40 cycles of extension at 95(C for 15 s
and 1 min at 60(C, and data collected during the last 30 s.
Threshold lines were adjusted to intersect ampliﬁcation
lines in the linear portion of the ampliﬁcation curves. The
software automatically recorded the Ct. The GAPDH gene
was used as an endogenous control and run together with
the samples for each ampliﬁcation reaction to allow for
normalization of different samples for RNA loading, cDNA
synthesis, and ampliﬁcation efﬁciencies and for comparison
of samples run at different times. The FBS control was used
as a calibrator (i.e., the fold change for control is 1.0).
Replicated data were normalized with GAPDH and the fold
change in gene expression relative to FBS control treatment
was calculated using the delta delta Ct method46.
STATISTICAL ANALYSIS
Data for NO and PGE2 release into conditioned media
were analyzed using a linear mixed effects model, including
the ﬁxed effect of treatment and the random effects of pool,
the interaction between treatment and pool, and repeated
measures within each treatment and pool combination.
Treatment effects were compared within each time point
using the multiple comparisons approach of Tukey. The
computations were performed using the MIXED procedure
of SAS47. Relative gene expression data determined using
Q-RT-PCR were analyzed considering the nonparametric
ANOVA approach of Friedman48. Differences were de-
clared statistically signiﬁcant when P! 0.05, unless other-
wise noted. Spearman’s rank correlations (r) between gene
expression data and biochemical data were computed
using the CORR procedure of SAS47.Results
THE EFFECT OF GLN AND CS ON GENE EXPRESSION
Bovine articular cartilage explants cultured with 50 ng/ml
rhIL-1b for 6, 24 and 48 h resulted in signiﬁcant (P! 0.01)
up-regulation of iNOS expression relative to control (Table
III). The large standard error for both IL-1 and IL-1 plus CS
treatments at 6 h was attributed to variation between pools of
animal tissue and not technical error within a replication. GLN
(5 mg/ml) down-regulated iNOSmRNAexpression from11.1-
fold to 4.5-fold in explants cultured for 24 h (Table III). CS
(20 mg/ml) added alone or in combination with GLN for 24 h
was as effective as GLN in suppressing iNOS transcripts
(Table III) but only the combination reduced iNOSexpression
to control levels. After 48 h, cytokine-stimulated explants
treated with CS or GLN and CS repressed iNOS mRNA
expression to control levels (Table III). The iNOS transcript of
explants treated with GLN alone at the 48 h time point was
not different from IL-1 stimulated explants (Table III).
Cartilage explants stimulated with 50 ng/ml rhIL-1b
demonstrated signiﬁcant elevation in COX-2 mRNA ex-
pression relative to control by 30-fold for 6 h post-
stimulation (Table III). Like iNOS mRNA expression at 6 h,
variability of COX-2 level of transcript at this time point was
due to differences between replications. At the 6 h time
point, GLN or CS used individually and used in combination
Table III
Relative gene expression of explants stimulated with rhIL-1b and
physiologically relevant concentrations of GLN and CS
Gene Treatment
IL-1 IL-1CGLN IL-1CCS IL-1CGLN
CCS
Mean fold change (GSE) in gene expression relative to
control 6 h post-stimulation
iNOS 87.7G 73.6a 4.1G 1.0a 26.7G 24.9a 4.1G 2.8a
COX-2 30.0G 13.3b 1.5G 0.9a 2.7G 2.5a 3.3G 3.1a
mPGEs1 8.7G 2.8b 4.5G 1.0a 5.4G 1.5b 4.9G 1.5a
Mean fold change (GSE) in gene expression relative to
control 24 h post-stimulation
iNOS 11.1G 3.1b 4.5G 1.9a 4.4G 0.6a 3.0G 0.8a
COX-2 7.7G 0.6b 3.2G 2.0a 7.1G 0.6b 3.4G 0.6a
mPGEs1 0.7G 0.1a 0.4G 0.1a 1.0G 0.3a 0.6G 0.2a
Mean fold change (GSE) in gene expression relative to
control 48 h post-stimulation
iNOS 9.4G 2.7b 3.1G 1.4b 2.3G 1.3a 1.2G 1.0a
COX-2 12.6G 4.0b 3.4G 0.7a 2.8G 1.0a 1.0G 0.8a
mPGEs1 4.8G 2.0a 1.6G 0.8a 1.5G 0.8a 0.8G 0.3a
IL-1Z 50 ng/ml rhIL-1b; IL-1CGLNZ 50 ng/ml rhIL-1b and
5 mg/ml GLN; IL-1CCSZ 50 ng/ml rhIL-1b and 20 mg/ml CS; IL-
1CGLNCCSZ 50 ng/ml rhIL-1b, 5 mg/ml GLN and 20 mg/ml
CS. Different superscripts for values within a row (i.e., one gene)
denote a signiﬁcant difference (P! 0.05) between treatments.
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(Table III). TheCOX-2gene for explants treatedwith 50 ng/ml
rhIL-1b was signiﬁcantly up-regulated by 8-fold and 13-fold
for 24 and 48 h post-stimulation, respectively (Table III). At
both time points, GLN suppressed the activation of the
COX-2 gene to control levels (Table III). Physiologically
relevant concentration of CS at 20 mg/ml did not repress
COX-2 transcript increased by IL-1 until 48 h (Table III). The
GLN and CS combination decreased COX-2 expression to
3.4-fold and 1.0-fold change for 24 and 48 h, respectively
(Table III), which is not different from control.
The transcript for mPGEs1, the terminal enzyme involved
in PGE2 synthesis was elevated by about 9-fold
(PZ 0.0008) relative to control, in explants cultured with
50 ng/ml rhIL-1b over a 6-h period (Table III). At this time
point, GLN alone and the nutraceuticals combination
repressed mPGEs1 mRNA expression to control levels
(Table III). No effect on mPGEs1 expression was found for
any of the treatments at 24 and 48 h (Table III).
THE EFFECT OF GLN AND CS ON NO AND PGE2 SYNTHESIS
NO released into conditioned media at 24 h after the
addition of treatment was increased with 50 ng/ml rhIL-1b to
21.39 mM from 5.98 mM for FBS control [Fig. 1(A)]. The
addition of CS or GLN plus CS suppressed NO release to
16.93 and 17.27 mM, respectively [Fig. 1(A)]. At 48 h, the
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Fig. 1. Mean (GSE) nitrite release into conditioned media 24 h (A)
and 48 h (B) after treatments are added. CtrlZ FBS control; IL-
1Z 50 ng/ml rhIL-1b; IL-1CGLNZ 50 ng/ml rhIL-1b and 5 mg/ml
GLN; IL-1C CSZ 50 ng/ml rhIL-1b and 20 mg/ml CS; IL-
1CGLNC CSZ 50 ng/ml rhIL-1b, 5 mg/ml GLN and 20 mg/ml
CS. Different superscripts indicate signiﬁcant differences at
P! 0.05.elevation in NO release with 50 ng/ml rhIL-1b was not
reduced by either nutraceutical [Fig. 1(B)].
Explants stimulated with 50 ng/ml rhIL-1b released
signiﬁcantly more PGE2 into media when compared to
control. After 24 h stimulation, PGE2 release was elevated
to 1986 pg/ml compared with basal PGE2 release at
169 pg/ml [Fig. 2(A)]. The addition of GLN and CS, or in
combination reduced PGE2 release induced by cytokine to
control levels [Fig. 2(A)]. The basal PGE2 release into
media 48 h post-treatment was 171 pg/ml [Fig. 2(B)]. This
level was elevated to 1122 pg/ml when 50 ng/ml rhIL-1b
was added [Fig. 2(B)]. GLN decreased PGE2 release due to
IL-1 by 68% [Fig. 2(B)]. Likewise, the combination resulted
in a 76% decline in PGE2 release induced by IL-1 [Fig. 2(B)].
CS addition to the explants in vitro tended (P! 0.10) to
decrease PGE2 release [Fig. 2(B)].
THE EFFECT OF GLN AND CS ON ENOS GENE EXPRESSION
Since the biochemical data on NO release conﬂicted with
the Q-RT-PCR data on iNOS gene expression proﬁle, we
decided to investigate the expression of the eNOS gene,
another isoform of the NO synthase enzyme. Only
a transient pattern of eNOS regulation by CS was
witnessed. The IL-1 mediated increase in eNOS transcript
of 3.3-fold at 24 h was signiﬁcantly (P! 0.05) reduced to
0.3-fold with 20 mg/ml CS. No signiﬁcant differences were
seen with the other treatments (data not shown).
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Fig. 2. Mean (GSE) PGE2 release into conditioned media 24 h (A)
and 48 h (B) after the addition of treatments. CtrlZ FBS control;
IL-1Z 50 ng/ml rhIL-1b; IL-1CGLNZ 50 ng/ml rhIL-1b and 5 mg/
ml GLN; IL-1C CSZ 50 ng/ml rhIL-1b and 20 mg/ml CS; IL-1C
GLNC CSZ 50 ng/ml rhIL-1b, 5 mg/ml GLN and 20 mg/ml CS.
Different superscripts indicate signiﬁcant differences at P! 0.05.
* Tended to be different than the IL-1 treatment (P! 0.10).
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To our knowledge, the present study is the ﬁrst to
describe the effect of GLN and CS attained in blood on
gene expression and synthesis of inﬂammatory mediators
using a cartilage explant culture. The concentration chosen
for GLN was 5 mg/ml while that for CS was 20 mg/ml. These
concentrations were at the low end of the range found in
blood after oral or intravenous administration37,41,42. Pre-
vious trials from our laboratory used concentrations which
are higher than the range found in the plasma of animals
administered GLN and CS49. Another novelty of this
research lies in the nutraceutical combination investigated.
Few in vitro studies have been conducted with the GLN and
CS combination although they are frequently marketed as
a combination. One study reported that they are synergis-
tic50, while another suggested they may be complemen-
tary49.
NO is implicated in the pathogenesis of arthritis. Normal
cartilage explants produce little NO51. On the contrary,
chondrocytes and the synovial membrane in OA and
rheumatoid arthritis (RA) patients produce NO abundantly
and so does cytokine-induced cartilage51e53. In fact,
activated articular chondrocytes produce more NO than
any other cells, including synoviocytes, hepatocytes and
macrophages3. Inducible forms of NO synthase are found in
cartilage and produce large amounts of NO in response to
IL-113. Both iNOS mRNA and protein concentrations are
higher in OA cartilage relative to healthy articular cartilage
and increase with severity of the degenerative joint
disease54. The ability of IL-1 to enhance iNOS transcript
was also evident in the present study (Table III)3. NO
suppresses proteoglycan synthesis by inhibiting the
process of sulfation on the glycosaminoglycan chains14,55.
Inhibition of prolyl hydroxylase coupled with the suppres-
sion of type II collagen synthesis was associated with the
release of large amounts of NO56. This inorganic free
radical also mediates the degradation of matrix components
via activation of MMPs13. Besides cartilage destruction, NO
has also been implicated as a mediator of inﬂammatory
responses12. Thus, the inhibition of NO synthesis may be
effective as a therapeutic route for OA.
GLN and CS have been used successfully for treating
chronic inﬂammatory arthritides. One of the mechanisms of
action of these compounds may be the suppression of NO
production. Previous work from our laboratory using ex-
plants from horses indicates decreased NO production with
250 mg/ml CS and with the combination of 500 mg/ml GLN
and 250 mg/ml CS49. Inhibition of NO with GLN occurred at
concentrations greater than 1 mg/ml in equine explants and
human chondrocytes27,30,49. Suppression of NO synthesis
with GLN was associated with iNOS mRNA and protein
repression29,30. In the current trial, CS alone and in
combination with GLN at physiological concentrations were
effective in reducing NO synthesis induced by IL-1 at 24 h
[Fig. 1(A)]. At 48 h of culture, nitrite has accumulated to the
same level for all treatments except for control [Fig. 1(B)].
These levels of NO in conditioned media may be explained
by transcriptional regulation of genes pertaining to the
enzymes responsible for synthesizing NO. Although the
levels of NO were signiﬁcantly reduced at 24 h, these were
marginal declines. Since NO and PGE2 can modulate the
activity of the other57, even transient regulation of NO may
affect the anti-inﬂammatory response to some extent.
The inducible form of the NO synthases is iNOS and
there are two constitutive isoforms, eNOS and nNOS. The
constitutive form of eNOS was initially thought to beconﬁned to endothelial cells while nNOS was localized to
the central and autonomic nervous systems9. However,
eNOS and nNOS have increasingly been identiﬁed in a lot
of different cell types including chondrocytes58. eNOS may
also be inducible since human eNOS gene contains
activator protein-1 (AP-1) site in its promoter region59. The
mitogen-activated protein kinase (MAPK) pathway is
activated by cytokines leading to AP-1 phosphorylation
and up-regulation of a number of genes associated with
cartilage catabolism60. Human OA chondrocytes express
elevated levels of nNOS61. To date, only the genes for
iNOS and eNOS and not nNOS in the bovine species have
been cloned and sequenced. Since eNOS mRNA levels
were not markedly affected at 48 h, the lack of treatment
effect on NO production could be in part due to the activity
of eNOS and potentially nNOS.
PGE2, another catabolic mediator in the pathogenesis of
OA is formed from a series of enzymatic reactions termed
the arachidonic acid cascade. It mediates synoviocyte
proliferation and is responsible for pain and inﬂammatory
responses. PGE2 enhances the degradative processes of
proteoglycans17,18. It is found in diseased joints and is
signiﬁcantly elevated in synovial ﬂuid of OA patients15,18.
Large amounts of PGE2 are synthesized by chondrocytes
that are exposed to IL-1 in vitro18. Bovine explant cultures
induced with IL-1 demonstrated signiﬁcant increase in
PGE2 from basal levels [Fig. 2(A,B)]. Elevated levels of
PGE2 depleted matrix components from intact articular
cartilage cultured in vitro62.
The induction of COX-2 is largely responsible for elevated
concentrations of PGE2
31,63. COX-2 expression is elevated
in cartilage specimens of OA and RA patients64,65. Findings
from the present study demonstrated the signiﬁcant up-
regulation of the COX-2 gene relative to control in response
to IL-1 for all time points (Table III) in accord with previous
reports31,66. Levels of PGE2 in our explant cultures were
positively correlated with COX-2 mRNA (rZ 0.81,
P! 0.0001) in agreement with Geng et al.66. Inhibiting
PGE2 release is an increasingly common strategy for
providing relief to patients affected with arthritis as
evidenced by the development of COX-2 inhibitors.
In clinical studies, GLN and CS have been consistently
beneﬁcial in improving the pain scores and inﬂammatory
responses of patients affected with OA22e25. In vitro results
from previous work in our laboratory and others demon-
strated declines in the inﬂammatory mediator, PGE2, with
GLN and CS supplementation26,31,49,67. In the present
study, GLN, CS alone or in combination reduced IL-1
induced PGE2 levels. The ability of GLN and CS to reduce
PGE2 synthesis in the present study can be explained by
their effect on COX-2 gene expression. Since there is a lag
time of about 12e18 h from the time the gene is expressed
to the time it is translated into protein, the COX-2 mRNA
data at 6 h does correspond to the PGE2 levels at 24 h
while mRNA data at 24 h has a similar proﬁle with PGE2
levels at 48 h. The ability of GLN to suppress COX-2 mRNA
expression by about 2-fold at 24 h post-stimulation parallels
the work by Largo et al.31 in human chondrocytes.
However, the concentration of GLN used in their study
was 1 mg/ml which is 200 times the concentration used in
our study. The present study substantiates the claim that
repression of COX-2 transcripts and eventually PGE2 is at
least one of the mechanisms GLN alone or together with CS
exert their analgesic effects.
The effect of these chondroprotective agents on terminal
PGE enzymes involved in the formation of PGE2 has not
been reported. In fact, we only know of one abstract that
392 P. S. Chan et al.: Glucosamine and chondroitin sulfate regulate inﬂammatory mediatorshas investigated this enzyme in chondrocytes68. There are
reports of concomitant regulation of COX-2, mPGEs1 and
PGE2
16,68. Transcripts of COX-2 and mPGEs1 are corre-
lated in the present study (rZ 0.43, P! 0.05). However,
differences in the timing for COX-2 and mPGEs1 induction
may be due to dissimilar regulatory sequences in these two
genes6. Explants treated either with GLN alone or in
combination with CS repressed IL-1 induced mPGEs1
expression at 6 h post-culture (Table III). Further studies on
the contribution of this brief regulation on mPGEs1 in
chondrocytes by the nutraceuticals are warranted.
Determining the mechanism of action behind GLN and
CS is essential to elucidating the beneﬁcial effects elicited
by these compounds in combating arthritic symptoms.
Understanding how these agents may regulate NO and
PGE2 is an active area of research. Besides being
proinﬂammatory, NO and PGE2 have the ability to increase
proteoglycan loss and decrease proteoglycan synthe-
sis14,18. Our results suggest a transient modulation of
mPGEs1 and NO synthase gene expression, and NO
synthesis by the nutraceuticals. Physiologically relevant
concentrations of GLN and CS repress COX-2 expression
that eventually translates into accompanying declines in
PGE2 synthesis. Thus, the ﬁndings in the present study
may explain at least in part how IL-1 induced proteoglycan
breakdown and decreased proteoglycan synthesis is
prevented in vitro69,70.
Results from the present study indicate that GLN and CS
may regulate the expression and synthesis of NO and PGE2,
providing a plausible explanation for the symptomatic relief
attributed to the administration of these compounds.
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